Scarica l'app Stockscreener
0.4341
3.21%
-0.0144
Precedente Chiudi:
$0.4485
Aprire:
$0.44
Volume 24 ore:
127.38K
Relative Volume:
0.48
Capitalizzazione di mercato:
$16.79M
Reddito:
-
Utile/perdita netta:
$-117.67M
Rapporto P/E:
-0.1405
EPS:
-3.09
Flusso di cassa netto:
$-101.06M
1 W Prestazione:
-7.24%
1M Prestazione:
-19.51%
6M Prestazione:
-86.90%
1 anno Prestazione:
-88.27%
Intervallo 1D:
$0.428
$0.4599
Intervallo di 1 settimana:
$0.4213
$0.49
Portata 52W:
$0.4115
$4.21
Athira Pharma Inc Stock (ATHA) Company Profile
Nome
Athira Pharma Inc
Settore
Industria
Telefono
(425) 620-8501
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Confronta ATHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.4341 | 16.79M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-04 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-09-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Iniziato | Rodman & Renshaw | Buy |
| 2022-10-17 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Downgrade | Jefferies | Buy → Hold |
| 2022-06-23 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Iniziato | BTIG Research | Buy |
| 2022-04-21 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Goldman | Neutral |
| 2020-10-13 | Iniziato | Goldman | Buy |
| 2020-10-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-13 | Iniziato | Jefferies | Buy |
| 2020-10-13 | Iniziato | Stifel | Buy |
Mostra tutto
Athira Pharma Inc Borsa (ATHA) Ultime notizie
ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com
Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World
Athira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News Summary - Benzinga
Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World
Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha
Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN
Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St
Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review
Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews
Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient
Athira to pay $4M to resolve research misconduct allegations - BioWorld Online
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN
Whistleblower Receives $200K After Alleging Scientific Research Misconduct - Whistleblower Network News
Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals
Biotech company agrees to pay $4 million to settle data falsification allegations - Retraction Watch
Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360
Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today
Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com
Bothell pharma company to pay $4 million over falsified research claims - MSN
Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law
Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa
Athira Pharma CEO sells shares worth $14,107 - Investing.com
Athira Pharma VP of Finance Sells Shares for $1,618 - Investing.com India
Athira Pharma VP of Finance Sells Shares for $1,618 By Investing.com - Investing.com Canada
JMP Securities Downgrades Athira Pharma (ATHA) - MSN
Athira Pharma Insider Ups Holding By 111% During Year - Yahoo Finance
Athira Pharma's SWOT analysis: stock faces challenges after trial setback - Investing.com India
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - The Manila Times
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND - GlobeNewswire
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by GSA Capital Partners LLP - Defense World
Crowdstrike Holdings Inc (CRWD-Q) QuotePress Release - The Globe and Mail
Athira Pharma's SWOT analysis: stock shifts focus after trial setback By Investing.com - Investing.com UK
Athira Pharma's SWOT analysis: stock shifts focus after trial setback - Investing.com
Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline - MSN
Athira exploring strategic alternatives after Alzheimer’s failure - BioPharma Dive
Athira Pharma Reports Q3 2024 Financial Results - TipRanks
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - The Manila Times
What You Didn’t Know About Athira Pharma Inc (NASDAQ: ATHA) This Week - Stocks Register
Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360
US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St
Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN
Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan
Athira Pharma faces Nasdaq delisting over share price - Investing.com
A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News
A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News
Athira Pharma Inc Azioni (ATHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Athira Pharma Inc Azioni (ATHA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '25 |
Sale |
0.56 |
10,826 |
6,083 |
35,841 |
| Litton Mark James | President and CEO |
Dec 31 '24 |
Option Exercise |
0.00 |
108,333 |
0 |
267,698 |
| Litton Mark James | President and CEO |
Jan 02 '25 |
Sale |
0.56 |
25,107 |
14,108 |
242,591 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
139,271 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
130,761 |
| Renninger Robert | VP of Finance |
Dec 31 '24 |
Option Exercise |
0.00 |
12,359 |
0 |
92,605 |
| Renninger Robert | VP of Finance |
Jan 02 '25 |
Sale |
0.56 |
2,881 |
1,619 |
89,724 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '24 |
Option Exercise |
0.00 |
36,667 |
0 |
92,245 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '25 |
Sale |
0.56 |
8,510 |
4,782 |
83,735 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):